A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

Abstract

Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients were eligible if they had relapsed MCL with 1–3 prior therapies. Patients were treated with gemcitabine 1000 mg/m² on days 1 and 8 and bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11, on a 21-day schedule. Twenty-six patients were evaluable for toxicity and 25 for response. The overall response rate was 60% and the median progression free survival was 11.4 months. The main adverse effects were hematological, with 40% and 48% of patients experiencing grade 3/4 thrombocytopenia and granulocytopenia, respectively. Bortezomib and gemcitabine is an active combination in relapsed and refractory MCL with clinically meaningful results. It offers a chemotherapy backbone to which other agents, less myelosuppressive, may be added.

Keywords:

• Mantle cell lymphoma
• bortezomib
• gemcitabine
• phase II

View correction statement:

Corrigendum

Acknowledgements

We would like to thank the following investigators who also contributed to or followed patients on the study: Drs. A. Belch, M. Cheung, S. Couban, W. Hasegawa, V. Kukreti, J. Kuruvilla, and D. White.

Declaration of interest: This trial was supported in part by research grants from the Canadian Cancer Society and Ortho Biotech. Eli Lilly Canada provided gemcitabine for the trial.